ValuEngine Downgrades Arch Therapeutics, Inc. (ARTH) to Sell

Arch Therapeutics, Inc. (OTCMKTS:ARTH) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Friday.

Other analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Arch Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of Arch Therapeutics in a research note on Monday, September 18th. Finally, Ifs Securities reissued an “outperform” rating on shares of Arch Therapeutics in a research note on Tuesday, July 25th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. Arch Therapeutics has an average rating of “Buy” and a consensus price target of $2.31.

Shares of Arch Therapeutics (OTCMKTS ARTH) opened at $0.59 on Friday. Arch Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $0.89.

WARNING: “ValuEngine Downgrades Arch Therapeutics, Inc. (ARTH) to Sell” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at

Arch Therapeutics Company Profile

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Receive News & Ratings for Arch Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply